Advertisement

Topics

Enanta Pharmaceuticals, Inc. Announces U.S. FDA Approval Of AbbVie???s MAVYRET (Glecaprevir/Pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6) In As Little As 8 Weeks

20:00 EDT 3 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Enanta Pharmaceuticals, Inc. Announces U.S. FDA Approval Of AbbVie???s MAVYRET (Glecaprevir/Pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6) In As Little As 8 Weeks

NEXT ARTICLE

More From BioPortfolio on "Enanta Pharmaceuticals, Inc. Announces U.S. FDA Approval Of AbbVie???s MAVYRET (Glecaprevir/Pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6) In As Little As 8 Weeks"

Quick Search
Advertisement
 

Searches Linking to this Story